WuXi Biologics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	21,790	18,675	17,034	15,269	10,290
Revenue Growth (YoY)	16.68%	9.63%	11.56%	48.38%	83.34%
Cost of Revenue	11,772	11,025	10,206	8,545	5,461
Gross Profit	10,019	7,651	6,828	6,724	4,829
Selling, General & Admin	2,313	2,147	1,789	1,433	1,001
Research & Development	853.37	766.44	785.82	682.82	501.58
Other Operating Expenses	-	-	23.47	-1.49	24.29
Operating Expenses	3,372	3,065	2,895	2,374	1,659
Operating Income	6,646	4,585	3,933	4,350	3,170
Interest Expense	-143.06	-157.59	-158.49	-64.38	-39.19
Interest & Investment Income	434.65	351.54	219.18	115.79	58.03
Currency Exchange Gain (Loss)	-267.45	-45.22	46.73	417.2	-32.58
Other Non Operating Income (Expenses)	-459.22	191.9	173.38	159.56	171.36
EBT Excluding Unusual Items	6,211	4,926	4,214	4,978	3,328
Gain (Loss) on Sale of Investments	1,045	-91.72	13.83	379.44	665.44
Other Unusual Items	-	-	-53.58	-	-
Pretax Income	7,257	4,834	4,174	5,358	3,993
Income Tax Expense	1,524	889.03	603.18	807.87	484.54
Earnings From Continuing Operations	5,733	3,945	3,571	4,550	3,509
Minority Interest in Earnings	-824.88	-589.29	-170.9	-129.62	-120.1
Net Income	4,908	3,356	3,400	4,420	3,388
Net Income to Common	4,908	3,356	3,400	4,420	3,388
Net Income Growth	46.25%	-1.28%	-23.09%	30.45%	100.63%
Shares Outstanding (Basic)	4,027	4,082	4,164	4,173	4,174
Shares Outstanding (Diluted)	4,176	4,227	4,349	4,376	4,422
Shares Change (YoY)	-1.22%	-2.80%	-0.62%	-1.04%	5.05%
EPS (Basic)	1.22	0.82	0.82	1.06	0.81
EPS (Diluted)	1.16	0.78	0.77	1.01	0.77
EPS Growth	47.93%	1.55%	-23.50%	31.17%	92.50%
Free Cash Flow	-	1,288	622.14	-326.72	-3,077
Free Cash Flow Per Share	-	0.30	0.14	-0.07	-0.70
Gross Margin	45.98%	40.97%	40.08%	44.04%	46.93%
Operating Margin	30.50%	24.55%	23.09%	28.49%	30.81%
Profit Margin	22.53%	17.97%	19.96%	28.95%	32.93%
Free Cash Flow Margin	-	6.89%	3.65%	-2.14%	-29.90%
EBITDA	7,910	5,849	4,928	5,069	3,622
EBITDA Margin	36.30%	31.32%	28.93%	33.20%	35.20%
D&A For EBITDA	1,263	1,263	995.46	718.63	452.24
EBIT	6,646	4,585	3,933	4,350	3,170
EBIT Margin	30.50%	24.55%	23.09%	28.49%	30.81%
Effective Tax Rate	21.00%	18.39%	14.45%	15.08%	12.13%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.